ArticleChem & bio engineering2024
Glycopolypeptide Coordinated Nanovaccine: Fabrication, Characterization, and Antitumor Immune Response.
Article in Chem & bio engineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Oxidation-activated nanotherapy boosts tumor immunity and disrupts tumor-nerve crosstalk to combat bone metastases and cancer pain.Science advances · 2026Article
- Noncanonical amino acid-aided synthesis of anti-PD-L1 bispecific nanobody for colon cancer immunotherapy.Communications biology · 2025Article
- Hydroxychloroquine-Derived Ionizable Lipid Facilitates Spleen-Tropic Transfection and Enhances Cancer Immunotherapy.Chem & bio engineering · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer nanovaccine is a frontier immunotherapy strategy, in which the delivery carrier can protect antigen and adjuvant from degradation, increase blood circulation half-life, and improve antigen permeability and presentation, thus enhancing the security and potency of nanovaccine. To address the barriers of antigen delivery, we design and fabricate a kind of intracellular pH-sensitive glycopolypeptide coordinated nanovaccine (OVA-HPGM-Mn) with ∼30% loading capacity of ovalbumin (OVA). The nanovaccine OVA-HPGM-Mn could specifically deliver antigen to dendritic cells (DCs) and effectively escape from endolysosomes to cytoplasm after 6 h of incubation, while the blank counterpart HPGM-Mn acted as an adjuvant to promote DCs maturation and increase the percentage of maturated cells to 26.5% from 11.8% in vitro. Furthermore, the mannosylated polypeptide nanovaccine prolonged the retention time of OVA for 72 h to facilitate 29.5% DCs maturation in lymph nodes, activated 48.8% CD8
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.